First AD

Second AD

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

ZUMA-3: CAR T Therapy for Adult Patients With ALL

OncLive News Network®

Experts in hematology oncology consider unmet needs for adult patients with relapsed/refractory ALL and reflect on the potential impact that FDA approval of CAR T cell therapy would have on the treatment landscape.

The Potential Future Impact of CAR T Cell Therapy in Adult ALL

The Evolving Treatment Landscape for ALL 

Using MRD to Monitor Therapeutic Response in  ALL 

The ZUMA-3 Trial: Study Design and Patient Population

The ZUMA-3 Trial: Efficacy and Safety Results

The ZUMA-3 Trial: Clinical Endpoints